Literature DB >> 15349966

In vitro absorption and secretory quotients: practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidates.

Victoria E Thiel-Demby1, Timothy K Tippin, Joan E Humphreys, Cosette J Serabjit-Singh, Joseph W Polli.   

Abstract

The absorptive (AQ) and secretory (SQ) quotients have been proposed as a novel experimental approach to quantify the modulation of intestinal absorption and secretion by P-glycoprotein (Pgp). Because these unidirectional assays inherently assess for the impact of Pgp, conclusions as to whether a compound is a Pgp substrate will be made from the data. Therefore, the objective of this study was to establish the relationship between AQ/SQ and the bidirectional efflux assay and to derive criteria to classify a compound as a Pgp substrate. AQ and SQ parameters were calculated for 331 compounds that had previously been evaluated in the bidirectional assay and the concordance of Pgp substrate classification between these methods assessed by establishing AQ/SQ criteria of increasing magnitude. The AQ and SQ values correctly identified 80 and 85% of the compounds as Pgp substrates/nonsubstrates relative to the bidirectional efflux assay. This study demonstrates that the optimal AQ and SQ value to classify compounds as Pgp substrates was 0.3 and provides a basis to deploy unidirectional efflux assays in the early stages of drug discovery, which would benefit from the twofold increase in throughput over current bidirectional transport assays.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15349966     DOI: 10.1002/jps.20166

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Synthesis and evaluation of analogs of 5'-(((Z)-4-amino-2-butenyl)methylamino)-5'-deoxyadenosine (MDL 73811, or AbeAdo) - An inhibitor of S-adenosylmethionine decarboxylase with antitrypanosomal activity.

Authors:  Anthony J Brockway; Oleg A Volkov; Casey C Cosner; Karen S MacMillan; Stephen A Wring; Thomas E Richardson; Michael Peel; Margaret A Phillips; Jef K De Brabander
Journal:  Bioorg Med Chem       Date:  2017-08-03       Impact factor: 3.641

2.  Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.

Authors:  Katrien Van Bocxlaer; Eric Gaukel; Deirdre Hauser; Seong Hee Park; Sara Schock; Vanessa Yardley; Ryan Randolph; Jacob J Plattner; Tejal Merchant; Simon L Croft; Robert T Jacobs; Stephen A Wring
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay.

Authors:  Oleg A Volkov; Casey C Cosner; Anthony J Brockway; Martin Kramer; Michael Booker; Shihua Zhong; Ariel Ketcherside; Shuguang Wei; Jamie Longgood; Melissa McCoy; Thomas E Richardson; Stephen A Wring; Michael Peel; Jeffrey D Klinger; Bruce A Posner; Jef K De Brabander; Margaret A Phillips
Journal:  ACS Infect Dis       Date:  2017-04-07       Impact factor: 5.084

4.  Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis.

Authors:  Bakela Nare; Stephen Wring; Cyrus Bacchi; Beth Beaudet; Tana Bowling; Reto Brun; Daitao Chen; Charles Ding; Yvonne Freund; Eric Gaukel; Ali Hussain; Kurt Jarnagin; Matthew Jenks; Marcel Kaiser; Luke Mercer; Elena Mejia; Andy Noe; Matt Orr; Robin Parham; Jacob Plattner; Ryan Randolph; Donna Rattendi; Cindy Rewerts; Jessica Sligar; Nigel Yarlett; Robert Don; Robert Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

5.  SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis.

Authors:  Robert T Jacobs; Bakela Nare; Stephen A Wring; Matthew D Orr; Daitao Chen; Jessica M Sligar; Matthew X Jenks; Robert A Noe; Tana S Bowling; Luke T Mercer; Cindy Rewerts; Eric Gaukel; Jennifer Owens; Robin Parham; Ryan Randolph; Beth Beaudet; Cyrus J Bacchi; Nigel Yarlett; Jacob J Plattner; Yvonne Freund; Charles Ding; Tsutomu Akama; Y-K Zhang; Reto Brun; Marcel Kaiser; Ivan Scandale; Robert Don
Journal:  PLoS Negl Trop Dis       Date:  2011-06-28

Review 6.  Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis.

Authors:  Stephen Wring; Eric Gaukel; Bakela Nare; Robert Jacobs; Beth Beaudet; Tana Bowling; Luke Mercer; Cyrus Bacchi; Nigel Yarlett; Ryan Randolph; Robin Parham; Cindy Rewerts; Jacob Platner; Robert Don
Journal:  Parasitology       Date:  2013-09-05       Impact factor: 3.234

7.  Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate.

Authors:  Melynda E Watkins; Steve Wring; Ryan Randolph; Seonghee Park; Kendall Powell; Lissa Lutz; Michelle Nowakowski; Ram Ramabhadran; Paul L Domanico
Journal:  J Pharm Sci       Date:  2016-12-14       Impact factor: 3.534

8.  Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.

Authors:  Andrew M Thompson; Andrew J Marshall; Louis Maes; Nigel Yarlett; Cyrus J Bacchi; Eric Gaukel; Stephen A Wring; Delphine Launay; Stephanie Braillard; Eric Chatelain; Charles E Mowbray; William A Denny
Journal:  Bioorg Med Chem Lett       Date:  2017-10-27       Impact factor: 2.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.